Document Type : Research Articles
Department of Cellular and Molecular Biology, University of Science and Culture, Tehran, Iran.
Immunology Research Center, Mashhad University of medical Sciences, Mashhad, Iran.
Medical Genetics Research Center, Faculty of Medical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran.
Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran
Department of Radiation oncology, Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.
Objective: CD44 is an important cell adhesion molecule that plays a key role in growth, invasion, proliferation and
metastasis of cancer cells. CD44 protein over-expression is associated with a poor prognosis of gastric cancer (GC) and
previous studies have shown that CD44 gene polymorphisms could affect survival and recurrence. In this study, we
tested the hypothesis that polymorphisms impacting on the CD44 signaling pathway may predict clinical outcomes in
patients with GC. Materials and Methods: DNA was extracted from blood of 150 healthy individuals and formalin-fixed
paraffin-embedded (FFPE) tumor tissue of 150 patients. The two polymorphisms rs187116 and rs7116432 were
studied by RFLP-PCR and sequencing techniques. Results: There was a strong significant correlation between single
nucleotide polymorphisms (SNPs) in the CD44 gene, tumor recurrence, and overall survival (p <0.0001). The existence
of a significant relationship between tumor recurrence and overall survival was proved in this study, with at least one
allele G for the polymorphism rs187116 and at least one allele A for polymorphism rs7116432. Conclusion: These results
provide evidence of a relationship between CD44 gene polymorphisms and clinical outcomes in our GC patients.
This result could help identify individuals with GC who have a high risk of tumor recurrence.